Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012.
Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012.
复制标题
DOI：
10.1371/journal.pone.0140765
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Newman LM
中科院分区：
文献类型：
--
作者：
Looker KJ;Magaret AS;May MT;Turner KM;Vickerman P;Gottlieb SL;Newman LM
1 型单纯疱疹病毒 (HSV-1) 通常会引起口腔唇溃疡，而 HSV-2 通常会引起生殖器溃疡。然而，HSV-1 日益成为生殖器感染的原因。此前，世界卫生组织估计了2003年和2012年的全球HSV-2负担。尚未估计HSV-1的全球负担。我们对 6 个世界卫生组织地区的文献检索中的 HSV-1 流行率数据进行了汇总，建立了恒定发病率模型，并使用 2012 年人口数据得出全球 0-49 岁人群中 HSV-1 感染流行和偶发的人数。为了估计生殖器 HSV-1，我们应用了生殖器感染事件比例的值。我们估计，2012 年，0-49 岁的 37.09 亿人（范围：3440-38.78 亿）患有 HSV-1 感染（67%），其中非洲、东南亚和西太平洋地区感染率最高。假设 15-49 岁人群中 50% 的感染事件是生殖器感染，则估计有 1.4 亿人（范围：67-2.12 亿）患有生殖器 HSV-1 感染，其中大多数发生在美洲、欧洲和西太平洋地区。 HSV-1 感染的全球负担是巨大的。生殖器 HSV-1 负担可能很大，但因地区而异。未来的控制工作，包括 HSV 疫苗的开发，除了 HSV-2 之外，还应考虑 HSV-1 的流行病学，特别是 HSV-1 对生殖器感染的相对贡献。
Herpes simplex virus type 1 (HSV-1) commonly causes orolabial ulcers, while HSV-2 commonly causes genital ulcers. However, HSV-1 is an increasing cause of genital infection. Previously, the World Health Organization estimated the global burden of HSV-2 for 2003 and for 2012. The global burden of HSV-1 has not been estimated. We fitted a constant-incidence model to pooled HSV-1 prevalence data from literature searches for 6 World Health Organization regions and used 2012 population data to derive global numbers of 0-49-year-olds with prevalent and incident HSV-1 infection. To estimate genital HSV-1, we applied values for the proportion of incident infections that are genital. We estimated that 3709 million people (range: 3440–3878 million) aged 0–49 years had prevalent HSV-1 infection in 2012 (67%), with highest prevalence in Africa, South-East Asia and Western Pacific. Assuming 50% of incident infections among 15-49-year-olds are genital, an estimated 140 million (range: 67–212 million) people had prevalent genital HSV-1 infection, most of which occurred in the Americas, Europe and Western Pacific. The global burden of HSV-1 infection is huge. Genital HSV-1 burden can be substantial but varies widely by region. Future control efforts, including development of HSV vaccines, should consider the epidemiology of HSV-1 in addition to HSV-2, and especially the relative contribution of HSV-1 to genital infection.